Finance and markets
PolyActiva is taking its high-precision glaucoma implant to global trials in a test for Australia’s biotech ambitions.
Head of private markets Martin Randall says private credit loan fees lack transparency, creating conflicts of interest and leaving investors in the dark.
Australia's startup secondary market sprang to life two years ago. Now, it is at a crossroads, with demand for liquidity far outstripping supply.
The former ANZ boss says Australia’s heavy regulation may benefit fintechs — if they can turn compliance into a competitive edge.
